Form 8-K - Current report:
SEC Accession No. 0001104659-18-007013
Filing Date
2018-02-07
Accepted
2018-02-07 07:45:34
Documents
12
Period of Report
2018-02-07
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a18-5540_18k.htm 8-K 25337
2 EX-99.1 a18-5540_1ex99d1.htm EX-99.1 23805
3 EX-99.2 a18-5540_1ex99d2.htm EX-99.2 13967
4 GRAPHIC g55401moi001.gif GRAPHIC 45615
5 GRAPHIC g55401moi002.gif GRAPHIC 117408
6 GRAPHIC g55401moi003.gif GRAPHIC 81091
7 GRAPHIC g55401moi004.gif GRAPHIC 144084
8 GRAPHIC g55401moi005.gif GRAPHIC 118001
9 GRAPHIC g55401moi006.gif GRAPHIC 81137
10 GRAPHIC g55401moi007.gif GRAPHIC 86897
11 GRAPHIC g55401moi008.gif GRAPHIC 88041
12 GRAPHIC g55401mmi001.jpg GRAPHIC 3474
  Complete submission text file 0001104659-18-007013.txt   1119152
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 18579278
SIC: 2834 Pharmaceutical Preparations